This clinical trial is focused on studying the long-term effects of a treatment for atopic dermatitis, a condition commonly known as eczema, which causes the skin to become itchy, red, and inflamed. The treatment being tested is called amlitelimab, which is given as an injection under the skin. The study aims to understand how safe and tolerable this treatment is for adults who have moderate to severe forms of atopic dermatitis.
Participants in the study will receive the amlitelimab treatment over a period of time, and researchers will monitor them to see how their condition responds. The study will also include a comparison with a group receiving a placebo, which is a substance with no active medication. This helps researchers determine the true effects of the treatment. The study will track any side effects or changes in the participants’ skin condition, as well as their overall health and quality of life.
The goal of this research is to gather information on the safety and effectiveness of amlitelimab for treating atopic dermatitis. By participating, individuals contribute to a better understanding of how this treatment can help manage the symptoms of eczema and improve the lives of those affected by this condition.
Czechia 
Denmark 
France 
Germany 
Italy 
Poland 
Spain 
The Netherlands 
